MwanzoVBIVQ • OTCMKTS
add
VBI Vaccines Inc
Bei iliyotangulia
$ 0.00050
Bei za siku
$ 0.00050 - $ 0.00060
Bei za mwaka
$ 0.00020 - $ 0.051
Thamani ya kampuni katika soko
elfu 7.17 USD
Wastani wa hisa zilizouzwa
elfu 56.23
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
OTCMKTS
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Mac 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 1.21M | 150.31% |
Matumizi ya uendeshaji wa biashara | 10.24M | -37.68% |
Mapato halisi | -17.90M | 35.50% |
Kiwango cha faida halisi | elfu -1.47 | 74.23% |
Mapato kwa kila hisa | — | — |
EBITDA | -11.26M | 40.75% |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Mac 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 12.60M | -68.82% |
Jumla ya mali | 75.44M | -41.27% |
Jumla ya dhima | 80.91M | -3.03% |
Jumla ya hisa | -5.47M | — |
hisa zilizosalia | 28.68M | — |
Uwiano wa bei na thamani | -0.00 | — |
Faida inayotokana na mali | -36.18% | — |
Faida inayotokana mtaji | -55.53% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Mac 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -17.90M | 35.50% |
Pesa kutokana na shughuli | -11.77M | 45.65% |
Pesa kutokana na uwekezaji | elfu -151.00 | 71.72% |
Pesa kutokana na ufadhili | elfu 843.00 | — |
Mabadiliko halisi ya pesa taslimu | -11.09M | 50.13% |
Mtiririko huru wa pesa | -4.40M | 70.09% |
Kuhusu
Variation Biotechnologies Inc., also known as VBI Vaccines Inc., is a biopharmaceutical company, headquartered in Cambridge, Massachusetts, with research facilities in Ottawa, Ontario, Canada, and a research and manufacturing site in Rehovot, Israel. Its Ottawa facility has approximately thirty researchers working with National Research Council of Canada to produce a COVID-19 vaccine—VBI-2902. In August VBI received CA$56 million from the Government of Canada to prepare its vaccine for clinical trials by the end of 2020. The company's CEO, Jeff Baxter, said that VBI-2902 is cheaper to produce than other vaccines. Wikipedia
Ilianzishwa
1965
Tovuti
Wafanyakazi
135
